Skip to Main Content
Diseases of the Digestive System - Liver, Phase II

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)

What is the purpose of this trial?

This research study is for people who may have abnormally high amount of fat and swelling (inflammation) of their liver along with some fibrosis (scarring) that is not related to excessive alcohol consumption. The medical term for this condition is nonalcoholic steatohepatitis (NASH) that has both high liver fat and inflammation (swelling) and fibrosis (scarring) that causes a stiff liver. This research study involves two investigational drugs (study drugs) as potential options to treat patients with NASH with liver fibrosis.

  • Trial with
    Pfizer Inc., U.S. Pharmaceuticals Group
  • Ages
    18 years - 75 years
  • Gender
    Both

Contact Information

For more information about this study, including how to volunteer, contact Elizabeth Szymanski

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    11/05/2023
  • Study HIC
    #2000027577